TY  - JOUR
AU  - Beyer, GJ
AU  - Miederer, M
AU  - Vranješ-Đurić, Sanja
AU  - Čomor, Jožef J.
AU  - Kunzi, G
AU  - Hartley, O
AU  - Senekowitsch-Schmidtke, R
AU  - Soloviev, D
AU  - Buchegger, F
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2757
AB  - This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for GT 120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 mug unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with Tb-149 is worthy of consideration as a new-generation radio-immunotherapeutic approach.
T2  - European Journal of Nuclear Medicine and Molecular Imaging
T1  - Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab
VL  - 31
IS  - 4
SP  - 547
EP  - 554
DO  - 10.1007/s00259-003-1413-9
ER  - 

@article{
author = "Beyer, GJ and Miederer, M and Vranješ-Đurić, Sanja and Čomor, Jožef J. and Kunzi, G and Hartley, O and Senekowitsch-Schmidtke, R and Soloviev, D and Buchegger, F",
year = "2004",
abstract = "This study demonstrates high-efficiency sterilisation of single cancer cells in a SCID mouse model of leukaemia using rituximab, a monoclonal antibody that targets CD20, labelled with terbium-149, an alpha-emitting radionuclide. Radio-immunotherapy with 5.5 MBq labelled antibody conjugate (1.11 GBq/mg) 2 days after an intravenous graft of 5.10(6) Daudi cells resulted in tumour-free survival for GT 120 days in 89% of treated animals. In contrast, all control mice (no treatment or treated with 5 or 300 mug unlabelled rituximab) developed lymphoma disease. At the end of the study period, 28.4%+/-4% of the long-lived daughter activity remained in the body, of which 91.1% was located in bone tissue and 6.3% in the liver. A relatively high daughter radioactivity concentration was found in the spleen (12%+/-2%/g), suggesting that the killed cancer cells are mainly eliminated through the spleen. This promising preliminary in vivo study suggests that targeted alpha therapy with Tb-149 is worthy of consideration as a new-generation radio-immunotherapeutic approach.",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
title = "Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab",
volume = "31",
number = "4",
pages = "547-554",
doi = "10.1007/s00259-003-1413-9"
}

Beyer, G., Miederer, M., Vranješ-Đurić, S., Čomor, J. J., Kunzi, G., Hartley, O., Senekowitsch-Schmidtke, R., Soloviev, D.,& Buchegger, F.. (2004). Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab. in European Journal of Nuclear Medicine and Molecular Imaging, 31(4), 547-554.
https://doi.org/10.1007/s00259-003-1413-9

Beyer G, Miederer M, Vranješ-Đurić S, Čomor JJ, Kunzi G, Hartley O, Senekowitsch-Schmidtke R, Soloviev D, Buchegger F. Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab. in European Journal of Nuclear Medicine and Molecular Imaging. 2004;31(4):547-554.
doi:10.1007/s00259-003-1413-9 .

Beyer, GJ, Miederer, M, Vranješ-Đurić, Sanja, Čomor, Jožef J., Kunzi, G, Hartley, O, Senekowitsch-Schmidtke, R, Soloviev, D, Buchegger, F, "Targeted alpha therapy in vivo: direct evidence for single cancer cell kill using Tb-149-rituximab" in European Journal of Nuclear Medicine and Molecular Imaging, 31, no. 4 (2004):547-554,
https://doi.org/10.1007/s00259-003-1413-9 . .